CRGX CARGO THERAPEUTICS INC revenue, earnings and financials
For the quarter ended June 30, 2025, CARGO THERAPEUTICS INC reported revenue of n/a, net income of −$49.9M and diluted EPS of −$1.04; for the fiscal year ended December 2024 revenue was n/a.
CRGX annual revenue and earnings
- Fiscal year ended Dec 2024: revenue n/a, gross profit n/a, operating income −$187M, net income −$168M (margin n/a), EPS −$3.72
- Fiscal year ended Dec 2023: revenue n/a, gross profit n/a, operating income −$96.7M, net income −$98.1M (margin n/a), EPS −$16.53
- Fiscal year ended Dec 2022: revenue n/a, gross profit n/a, operating income −$34.8M, net income −$41.0M (margin n/a), EPS −$104.40
CRGX quarterly revenue and earnings
- Quarter ended Jun 30, 2025: revenue n/a, net income −$49.9M, EPS −$1.04
- Quarter ended Mar 31, 2025: revenue n/a, net income −$84.5M, EPS −$1.77
- Quarter ended Dec 31, 2024 (from the annual report): revenue n/a, net income −$45.4M, EPS −$0.95
- Quarter ended Sep 30, 2024: revenue n/a, net income −$41.9M, EPS −$0.88
- Quarter ended Jun 30, 2024: revenue n/a, net income −$44.3M, EPS −$1.02
- Quarter ended Mar 31, 2024: revenue n/a, net income −$35.8M, EPS −$0.87
- Quarter ended Dec 31, 2023 (from the annual report): revenue n/a, net income −$32.1M, EPS $78.76
- Quarter ended Sep 30, 2023: revenue n/a, net income −$35.5M, EPS −$47.37
- Quarter ended Jun 30, 2023: revenue n/a, net income −$17.9M, EPS −$26.56
- Quarter ended Mar 31, 2023: revenue n/a, net income −$12.7M, EPS −$21.36
- Quarter ended Dec 31, 2022 (from the annual report): revenue n/a, net income −$13.7M, EPS n/a
- Quarter ended Sep 30, 2022: revenue n/a, net income −$12.3M, EPS −$28.38
- Quarter ended Jun 30, 2022: revenue n/a, net income −$10.2M, EPS n/a
- Quarter ended Mar 31, 2022: revenue n/a, net income −$4.76M, EPS n/a
CRGX cash flow, buybacks and dividends
- Fiscal year ended Dec 2024: operating cash flow −$140M, share buybacks n/a
- Fiscal year ended Dec 2023: operating cash flow −$81.2M, share buybacks n/a
- Fiscal year ended Dec 2022: operating cash flow −$29.1M, share buybacks n/a
CRGX balance sheet
- Jun 30, 2025: cash $108M, total assets $259M, total liabilities $20.9M, shareholders' equity $238M
- Mar 31, 2025: cash $61.8M, total assets $362M, total liabilities $79.5M, shareholders' equity $282M
- Dec 31, 2024: cash $64.4M, total assets $414M, total liabilities $53.8M, shareholders' equity $360M
- Sep 30, 2024: cash $71.2M, total assets $451M, total liabilities $50.1M, shareholders' equity $401M
- Jun 30, 2024: cash $154M, total assets $490M, total liabilities $53.9M, shareholders' equity $436M
- Mar 31, 2024: cash $81.5M, total assets $422M, total liabilities $49.2M, shareholders' equity $373M
- Dec 31, 2023: cash $406M, total assets $453M, total liabilities $47.7M, shareholders' equity $405M
- Sep 30, 2023: cash $60.3M, total assets $82.4M, total liabilities $41.7M, shareholders' equity −$109M
Is CRGX profitable?
No. CARGO THERAPEUTICS INC lost $222M over the last four quarters.
What is CRGX's EPS?
Diluted earnings per share over the last four quarters were −$4.64; −$1.04 in the latest quarter.